[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655950":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":13,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":42,"collaborators":13,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":13,"studyType":59,"phases":13,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":68,"whyStopped":13,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Al-Azhar University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Evaluation of Hair Changes in Female Patients with Type 2 Diabetes Mellitus Versus Non-Diabetic Controls: A Clinical and Dermoscopic Cross-Sectional Study","Clinical Hair Assessment:\n\n1. Hair loss pattern (diffuse, frontal, vertex, etc.)\n2. Duration of hair loss (months\u002Fyears)\n3. Hair pull test results (positive\u002Fnegative)\n\nDermoscopic (Trichoscopic) Features:\n\n1. Hair shaft diameter variability (%)\n2. Presence of yellow dots, white dots, or peripilar signs\n3. Follicular density (number\u002Fcm²)\n4. Miniaturized hair count\n\nMetabolic and Laboratory Parameters:\n\n1. BMI (kg\u002Fm²)\n2. HbA1c (%)\n3. Serum Ferritin (ng\u002FmL)\n4. Vitamin D3 (ng\u002FmL)\n5. TSH (µIU\u002FmL)\n6. Hemoglobin (g\u002FdL)\n7. ESR (mm\u002Fhr)\n\nDiabetes-Related Measures:\n\n1. Duration of diabetes (years)\n2. Presence of diabetic neuropathy (yes\u002Fno)\n\nPatient-Reported Outcomes\n\nVisual Analog Scale (VAS) for hair loss severity (ludwing scale-sinclair scale)\n\nPhysician's Global Assessment of hair changes","1 year",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_CONTROL","CROSS_SECTIONAL","The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.\n\nInclusion criteria •\n\nCases:\n\nFemale patients aged 20-60 years Diagnosed with type 2 diabetes mellitus for at least 1 year HbA1c ≥ 6.5% o Consent to participate\n\n* Controls:\n\nAge-matched healthy females (no history of diabetes or insulin resistance) Normal fasting blood sugar (\\\u003C100 mg\u002FdL) and HbA1c (\\\u003C5.7%) No known chronic illness Consent to participate Exclusion Criteria (for both groups)\n\n* Current pregnancy or lactation\n* Thyroid dysfunction\n* Polycystic ovary syndrome (PCOS) • Anemia (Hb \\\u003C 10 g\u002FdL)\n* History of chemotherapy, radiotherapy, or recent acute illness\n* Scalp diseases (e.g., tinea capitis, scarring alopecia)\n* Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone)\n\nAll patients and control will undergo:\n\n1\\. Full history taking 2. Clinical Assessment All participants will undergo generalized dermatological examination including the scalp and body hair. The following aspects will be documented: A. General Scalp Examination • Hair density: visual inspection (reduced, normal) • Scalp condition: erythema, scaling, atrophy, scarring • Presence of inflammation or follicular hyperkeratosis • Hair shaft fragility or breakage • Sebum level: dry, normal, oily\n\nB. Hair Loss Type Classification Hair loss will be clinically categorized into one of the following types:\n\n1. Telogen effluvium (TE) Diffuse shedding, positive hair pull test\n2. Female pattern hair loss (FPHL) Frontal or vertex thinning with preserved frontal hairline\n3. Alopecia areata (AA) Patches of non-scarring alopecia\n4. Chronic diffuse hair loss Shedding \\>6 months without clear pattern C. Hair Pull Test • Performed by grasping \\~50 hairs from the frontal, parietal, and occipital regions • Considered positive if \\>6 hairs are easily extracted • Helps diagnose active shedding, especially in TE 3. Dermoscopic (Trichoscopic) Assessment Dermoscopy will be performed using a handheld dermoscope ( dermasight DS175 -cutechs LLC, Cairo, Egypt ) at 10× magnification, with or without immersion fluid.\n\nA. Sites Examined\n\n* Frontal scalp (midline, 2 cm behind hairline)\n* Vertex\n* Occipital region (serves as internal control)\n\nEach site will be examined systematically, and the following features will be documented:\n\nB. Dermoscopic Parameters Hair shaft diameter diversity (HSDD) \\>20% variation Yellow dots Peripilar signs (brown halos) Short vellus hairs Thin hairs \\\u003C30 μm Empty follicular openings Black dots Exclamation mark hairs Broken \u002F dystrophic hairs\n\n4\\. Blinding and Reproducibility\n\n• Two independent dermatologists will assess dermoscopic images. • In case of disagreement, a third reviewer will be consulted. • Observers will be blinded to diabetic status to minimize bias.\n\n5\\. Photographic Documentation • High-resolution digital images of scalp regions 6. Laboratory investigations:\n\nThe following laboratory serum tests will be done:\n\n1. Complete blood count.\n2. serum ferritin.\n3. Thyroid stimulating hormone.\n4. serum vitamin D3.\n5. Erythrocyte sedimentation rate.\n6. Glycated hemoglobin.","The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.\n\nThe patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.\n\nInclusion criteria • Cases: o Female patients aged 20-60 years o Diagnosed with type 2 diabetes mellitus for at least 1 year o HbA1c ≥ 6.5% o Consent to participate • Controls: o Age-matched healthy females (no history of diabetes or insulin resistance) o Normal fasting blood sugar (\\\u003C100 mg\u002FdL) and HbA1c (\\\u003C5.7%) o No known chronic illness o Consent to participate Exclusion Criteria (for both groups) • Current pregnancy or lactation • Thyroid dysfunction • Polycystic ovary syndrome (PCOS) • Anemia (Hb \\\u003C 10 g\u002FdL) • History of chemotherapy, radiotherapy, or recent acute illness • Scalp diseases (e.g., tinea capitis, scarring alopecia) • Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone).",[20],{"name":21,"affiliation":5,"role":22},"Basma Alsayed risha, lecturer","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":13,"email":28},"Heba khaled younes, resident","CONTACT","+201025858377","drmedhatyoness@gmail.com",[30],{"facility":31,"status":13,"city":32,"state":33,"zip":13,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":13},"Al Zahraa hospital","Cairo","Cairo Governorate","Egypt","EG",{"type":37,"coordinates":38},"Point",[39,40],31.24967,30.06263,{"lat":40,"lon":39},{"type":22,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Heba Khaled Younes Mohamed","resident","100655950","hair-changes-in-females-with-type-2-diabetes-clinical-and-trichoscopic-examination-100655950",false,"NCT07817277","Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination","Evaluation of Hair Changes in Female Patients With Type2 Diabetes Mellitus Versus Non-Diabetic Controls :A Clinical and Dermoscopic Cross-Sectional Study","TrichoscopyDM2","Inclusion Criteria:\n\n* Cases:\n\n  * Female patients aged 20-60 years\n  * Diagnosed with type 2 diabetes mellitus for at least 1 year\n  * HbA1c ≥ 6.5% o Consent to participate\n\n    * Controls:\n  * Age-matched healthy females (no history of diabetes or insulin resistance)\n  * Normal fasting blood sugar (\\\u003C100 mg\u002FdL) and HbA1c (\\\u003C5.7%) o No known chronic illness\n  * Consent to participate\n\nExclusion Criteria:\n\n* Current pregnancy or lactation\n\n  * Thyroid dysfunction • Polycystic ovary syndrome (PCOS)\n  * Anemia (Hb \\\u003C 10 g\u002FdL)\n  * History of chemotherapy, radiotherapy, or recent acute illness\n  * Scalp diseases (e.g., tinea capitis, scarring alopecia)\n  * Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone)","FEMALE","20 Years","60 Years",{"count":57,"type":58},130,"ESTIMATED","OBSERVATIONAL","The aim of this thesis is to investigate the effect of diabetes mellitus on hair by assessing and comparing clinical and dermoscopic hair changes in diabetic patients versus age and sex-matched healthy controls.",[62,63,64],"Diabete Mellitus","Female Androgenetic Alopecia","Dermoscopy",[64,66,67],"FPHL","DM2","NOT_YET_RECRUITING","2026-09-11",{"date":71,"type":72},"2026-09-14","ACTUAL",{"date":74,"type":58},"2026-10-01",{"date":76,"type":58},"2027-03-01",{"name":5,"class":6},1]